Merck and Pfizer have reported negative results from the Phase III JAVELIN Ovarian 200 trial that investigated the efficacy and safety of avelumab alone or in combination with pegylated liposomal doxorubicin (PLD) compared with PLD for the treatment of ovarian cancer.
The trial failed to meet the prespecified primary objectives of overall survival (OS) or progression-free survival (PFS) in patients who were resistant or refractory to platinum chemotherapy.
Go deeper with GlobalData
Avelumab safety profile was reported to be consistent with that observed in the overall JAVELIN clinical development programme and no new safety signals associated with avelumab alone or in combination were found.
Merck Biopharma research and development executive vice-president and global head Luciano Rossetti said: “Although OS and PFS did not reach statistical significance, study results indicate potential clinical activity of the combination of avelumab and chemotherapy which will be analysed further.
“We thank the patients, their families and the investigators who participated in the JAVELIN Ovarian 200 trial, and wish to underscore that the alliance remains committed to driving advances in ovarian cancer.”
The trial featured a multicentre, randomised study design and included 566 women with ovarian cancer resistant or refractory to platinum chemotherapy.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOverall, the JAVELIN trial comprised around 30 clinical programmes and more than 9,000 patients across 15 tumour types.
